

Organized by:



Under the High Patronage of  
Mr Emmanuel MACRON  
President of the French Republic



Funded by the  
European Union



# Welcome to HealthTech Innovation Days October 4&5 2021 In Paris\* & virtually

*\*At the Peninsula Hotel: Avenue des Portugais, 75116 Paris, France*



**Maryvonne Hiance**  
**President of HealthTech For Care**



Dear attendees,

Welcome to the third edition of HealthTech Innovation Days (HTID®)!

Healthcare access and treatment for every patient are a societal priority. Today, 10% of GDP is spent on healthcare with 27,000 medical technologies in Europe. These numbers show that many innovative healthcare companies and SMEs are looking to bring their innovations to patients and meet the medical challenges of tomorrow.

The main objective of this event is to foster collaborations within the European healthcare and life sciences ecosystems and to accelerate the commercialization of new drugs and therapeutic solutions on the market. Through HTID®, we gather key players in health innovation, global pharmaceutical companies, investors, political representatives and patient organizations for making this event impactful to bring their pivotal perspective to the table. For the first time this year, we have collaborated with European clusters in order to increase the number of European experts and companies.

HTID® is also an opportunity to discuss tomorrow's health major challenges with European experts with topics around investment and development of the health sector in Europe.

Placed for the third consecutive year under the High Patronage of Mr. Emmanuel Macron, President of the French Republic, HTID® will take place in the presence of institutional personalities: Mrs. Agnès Pannier-Runacher, Minister Delegate for Industry, Mr. Alain Godard, CEO of the European Investment Fund, Mr. Christian Pierret, former Minister of Industry, Mr. Saint-Martin, General Reporter of the French Commission of Finance, and Thierry Breton, European Commissioner for Internal Market.

---

**Jean-Marc Bourez**  
**EIT Health France and Services &  
Investments Managing Director**



Dear participants,

I am delighted to see that this third edition of the HealthTech Innovation Days will gather again high representatives from national and European Institutions.

Indeed, almost a year after President Emmanuel Macron's 2020 HealthTech Innovation Days opening speech, how far have we come in addressing the challenges identified during the Covid-19 crisis?

A few months ahead of France's Presidency of the European Union, the Minister for Industry, Ms. Agnès-Pannier Runacher will be invited to talk with us about the prospects for health innovation in Europe.

Likewise, the CEO of the European Investment Fund, Alain Godard and I will announce the names of the first members of the Venture Centre of Excellence (VCoE), the co-investment programme cooperated with EIT Health.

The VCoE had benefited from an anchor investment of 150 million euros from the European Commission as announced in 2020 by EU Commissioner for the Internal Market Thierry Breton.

Thanks to the implication of private investors and the involvement of public actors during the HTIDs, we can bet that this new edition will be followed by numerous investments for companies developing the health solutions of tomorrow.

## HealthTech Innovation Days – HTID®



The HTID® event provides a place for promising European life sciences companies to accelerate their growth and bring innovation to patients. The forum is taking place on October 4&5 2021 in a hybrid format, combining in-person presentations, panels and one-on-one meetings in Paris with a virtual platform for those unable to attend in person.

Organized by HealthTech For Care and EIT Health, HTID® objectives are to enable partnerships between international healthcare companies as well as to secure funding from international, specialized healthcare investors. The HealthTech Innovation Days are sponsored by international pharmaceutical companies, industrial companies and key support in the healthtech space. Placed for the third consecutive year under the High Patronage of Mr Emmanuel Macron, President of the French Republic, HTID® will take place in the presence of several institutional representatives: M. Thierry Breton, European Commissioner for the Internal Market, Mrs Alexandra Dublanche, Vice-President of the Île-de-France Regional Council, Mrs Agnès Pannier-Runacher, Minister for Industry, M. Christian Pierret former Minister for Industry, M. Laurent Saint-Martin, General Rapporteur of the National Assembly's Finance Committee, M. Alain Godard, CEO of the European Investment Fund.

### What does HTID provide access to?



#### Private meetings:

*Meet investors and innovative companies from across Europe and set up partnerships*



#### Sessions:

*Roundtables led by international experts on key topics of trends*



#### Networking event:

*Exchange with key players from the European health ecosystem*

## HealthTech For Care, Co-organizer of HealthTech Innovation Days



The HealthTech For Care Endowment Fund is designed to support and promote access to care for all and, in particular, new medical technologies and drugs. The missions of the endowment fund are organized around three main areas: supporting the development of the entire healthcare ecosystem, accelerating the development of innovative therapies and medicines, and promoting better access for patients to the healthcare system in France and Europe. HealthTech For Care is supported by its founder France Biotech and the network of French health cluster: Atlanpole biotherapies, BioValley France, EuroBioMed, LyonBioPole, Medicen and the cluster NSL. The Endowment Fund is also supported by many European players: Asebio, BIO Deutschland, BioWin, CEBR, Federchimica Assobiotech, flanders.bio, Irefi, LifeSci Advisors, P-BIO, SwendenBIO and Swiss Biotech.

## France Biotech, Founder of HealthTech For Care



Founded in 1997, France Biotech is an independent association that brings together HealthTech entrepreneurs and their expert partners. It actively contributes to meet the many challenges of the HealthTech industry (i.e. companies' financing, innovation-related taxes, regulatory and market access related issues) and offers concrete competition and solutions through its commissions and working groups. The goal is to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients.

France Biotech has founded and is developing the "HealthTech For Care" fund to strengthen the ability to federate, structure and encourage cooperation between the various stakeholders in the health tech sector in France and Europe. France Biotech is chaired by Franck Mouthon, CEO of TheraNexus.

## EIT Health, Co-organizer of HealthTech Innovation Days



Funded by the  
European Union



Europe faces a turning point in health. An ageing population, the rising burden of chronic disease, and rowing multi-morbidity are all placing pressure on health systems across Europe.

EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. That's why we call this the 'knowledge triangle'.

From our headquarters in Munich, six regional Innovation Hubs and InnoStars cluster, which brings together organisations from regions in which the overall pace of innovation is more moderate, we provide an ecosystem in which fresh thinking can thrive. Our Regional Innovation Scheme further expands our presence in 13 countries across Central, Eastern and Southern Europe. EIT Health also leads the development of the EIT Hub in Israel, which connects innovators across Europe to other key thriving ecosystems beyond the EU. EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Our ambition is to enable people in Europe to live longer, healthier lives by transforming businesses and delivering new products and services that can progress healthcare in Europe and strengthen our economy.

EIT Health: Together for healthy lives in Europe.



Backed by the European Commission, EIT Health and the European Investment Fund (EIF) are partnering to operate the [Venture Centre of Excellence \(VCoE\)](#).

The VCoE is a first of its kind Open Innovation programme connecting investors and other key stakeholders from the life science and healthcare ecosystems to highly qualified pan-European start-ups.

This collaboration between EIT Health, one of the world's largest life science consortia, and EIF, the largest and most influential investor in European venture capital, will catalyse €2 billion in life science investment over the coming 15 years and is expected to benefit more than 200 SMEs.

The VCoE programme is operated by EIT Health, operationally based in Paris, in partnership with the European Investment Fund, in Luxembourg.

Following the official launch of the Venture Centre of Excellence (VCoE) programme alongside the European Investment Fund (EIF) and [the announcement of the European Commission's €150 million anchor investment](#), the third edition of HTID® will allow selected European innovative healthcare companies to meet VCoE members for the first time. Moreover, they will learn about the programme in detail, including their ability to benefit from the programme's support of their upcoming equity fundraising rounds.

# OUR PARTNERS

Click on the logos to access the collaborator's websites



Platinum



Super Gold



Gold



Silver



Bronze





# Discover our long-term partners



With Amgen Innovations, we are strengthening our commitment to healthcare and research players in France. Concretely, we act as a catalyst around three key actions that structure this unprecedented programme: to undertake partnerships with start-ups to reinvent the health path, to support calls for research projects to discover the therapeutic innovations of tomorrow and to strengthen our support to caregivers facing the challenges of their profession. Associating biological and technological progress with human and social sciences opens up the field of possibilities. Convinced of the richness of the French ecosystem in terms of innovation, through Amgen Innovations, we wish to contribute to the emergence of healthcare solutions that have meaning for patients and healthcare professionals.



**BNP PARIBAS**  
The bank for a changing world

BNP Paribas is the European Union's leading bank in terms of revenues and key player in international banking.

The Group supports all its customers (individuals, associations, entrepreneurs, SMEs and institutions) in the success of their projects through its financing, investment, savings and protection solutions. BNP Paribas holds key positions in its three operating divisions:

- Retail Banking division brings together all of the Group's retail activities and specialised business lines;
- Investment & Protection Services includes specialised businesses offering a wide range of savings, investment and protection services;
- Corporate & Institutional Banking division offers tailored financial solutions for corporate and institutional clients, including capital markets issuance, financing, risk management and hedging. By matching the financing needs of companies with the investment opportunities sought by institutional investors, its financial solutions create value while contributing to the financing of the economy.



ICOSA is business-oriented European IP Law firm, dedicated to Healthcare (from Pharma to medical device and AI-related inventions), Food and Greentech.

With 45 employees, ICOSA is a lively and alert law firm, with high technical level and the following IP skills:

- Build-up IP Rights portfolios,
- Help in defining and implementing IP Strategies,
- Audit and Due Diligence in the framework of fund raising or acquisition,
- Bring IP intelligence and awareness to Investors and CEOs.



Invest Securities is an independent brokerage company with a complementary business unit including brokerage, equity research team and issuer services. We provide solutions adapted to companies, institutional investors as well as to fund managers.

Within Allinvest, Invest Securities benefits from the synergies of the finance company and is ranked as the leading listing sponsor on the Euronext and Euronext Growth markets.



Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2020, Servier employs 22,500 people worldwide.

Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities, from research to support beyond the pill.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.



Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company

builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.



## OUR COLLABORATIONS

*Click on the logos to access the collaborator's websites*



AseBio is the Spanish Bioindustry Association. ASEBIO brings together companies, associations, foundations, universities, research and technology centers that carry out activities directly or indirectly related to biotechnology in Spain. Since 1999, ASEBIO has been acting as a meeting and promotion platform for those organizations interested in stimulating the national biotechnology scene.



Biotechnologie-Industrie-Organisation Deutschland e.V.

As the sector association of the German biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences. The Berlin-based association currently has over 350 members.



THE HEALTH CLUSTER OF WALLONIA

The BioWin competitiveness cluster brings together all the innovation system players in Wallonia's life science field, with the goal of stimulating regional economic redeployment. Initially, its role was largely focused on the development, selection and monitoring of collaborative research and innovation (R&I) projects involving universities, research centers, academic hospitals and industries. BioWin currently represents 250 member companies.



Council of European BioRegions

CEBR is a membership-driven network of life science clusters and regional ecosystems across Europe, representing over 40 subscription members and a large number of cluster partners across the world. Together, we represent and support a critical mass of SMEs, and hundreds of universities and research centres.



Associazione nazionale per lo sviluppo delle biotecnologie

Assobiotech, the Italian Association for the Development of Biotechnology, part of Federchimica, represents approximately 130 companies and science and technology parks operating in healthcare and bioeconomy which includes agriculture, industry and environment.



flanders.bio is the independent dynamic cluster for the life sciences industry in Flanders, Belgium, with more than 330 members in Belgium and abroad. flanders.bio strengthens the Flemish life sciences and biotechnology ecosystem by facilitating partnering among its members.



IREFI – Institute for Economic Relations France-Italy is an independent "bilateral" Institute whose main mission is to facilitate business relations between France and Italy.



LifeSci Advisors are the global leading investor relations firm within Life Sciences. We combine deep domain life sciences expertise with decades of experience in capital markets to deliver services designed to increase our clients' visibility within the investment community.



Portugal's Biotechnology Industry Organization  
Associação Portuguesa de Biotecnologia

Portugal's Biotechnology Industry Organization (P-BIO) is the only association that brings together the vast majority of companies linked to the biotechnology and life sciences sector. Since it was founded in 1999, it has been the cornerstone for development and support of biotechnology in Portugal.



The Swedish Life Science Industry Organization

SwedenBIO represent the leading life science companies in Sweden. SwedenBIO has an innovative life science industry, strong academia and world leading infrastructure for research. SwedenBIO is the national non-profit association for the life science industry in Sweden, with almost 300 members.



The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.

# Agenda

Monday, 4 October

*On site 1-on-1 meetings from 7:00am to 7:30pm CET*  
*Virtual 1-on1 meetings: 24 hours / day*



Tuesday, 5 October

*On site 1-on-1 meetings from 07:00am to 06:00pm CET*  
*Virtual 1-on1 meetings: 24 hours / day*

Wednesday, 6 October

*During this day we keep doing virtual meetings*  
*Virtual 1-on1 meetings: 24 hours / day*

## Agenda

*Scan the QR Code to discover the speakers  
and watch the conference in live*



## 1-On-1 meeting website



Conferences location: Salon Etoile & Live : <https://vimeo.com/event/1291509>

Lunch: At the Lobby Restaurant & The Kleber Terasse from 12:00pm to 2:00pm  
Cocktail: At the Lobby Restaurant & The Kleber Terasse at 7:40pm

## Satellite events

*These satellite events will allow to deepen the discussion about major topics to improve the development of innovative European healthcare companies.*

### Thermo Fisher Scientific

*«Accelerating Innovative Therapies  
to Patients in a Post Pandemic  
World»*

**Wednesday, 6 October**  
**From 1:00PM–4:30PM CET**

### McDermott Will & Emery LLP

*«McDermott Paris Life Sciences  
Forum»*

**Thursday, 7 October**  
**From 3:00PM–6:00PM CET**



## NOTES

This image shows a full page of blank handwriting practice paper. It features 20 evenly spaced, horizontal blue lines running across the entire width of the page. The lines are thin and consistent in color, providing a guide for letter height and placement. There are no margins, text, or other markings on the paper.

## NOTES

[illegible]

## NOTES


[illegible]

# The Peninsula Plan


Avenue des Portugais, 75116 Paris, France



## Ground Floor



## First Floor



Wifi:  
PPRHTID

## OUR SUPPORTS



## FOLLOW US



<https://htfc-eu.com/htid/>



[https://twitter.com/HTID\\_Paris](https://twitter.com/HTID_Paris)



<https://www.linkedin.com/company/htid/>



[HTFC Channel](#)

## CONTACTS

**Nathalie Donne**

Business Advisor

[nathalie.donne@insead.com](mailto:nathalie.donne@insead.com)

+33(0)6 67 67 44 97

**Estelle Metzger**

Project Manager

HealthTech For Care

[estelle.metzger@htfc-eu.com](mailto:estelle.metzger@htfc-eu.com)

+33(0) 6 38 03 80 60

**Solène Goupy**

Communication Manager

HealthTech For Care

[solene.goupy@htfc-eu.com](mailto:solene.goupy@htfc-eu.com)

+33(0) 6 38 03 80 19

**Jérôme Fabiano**

External Affairs Officer

EIT Health France

[jerome.fabiano@eithealth.eu](mailto:jerome.fabiano@eithealth.eu)

+33(0)6 42 25 73 41

**Isaac Mideelmann**

VCoE Programme Director

EIT Health France

[isaac.middelmann@eithealth.eu](mailto:isaac.middelmann@eithealth.eu)

+33(0)6 86 41 62 85

**Martina Cortini**

Communication Manager

EIT Health France

[martina.cortini@eithealth.eu](mailto:martina.cortini@eithealth.eu)

+33(0)7 85 26 08 49

**Najette Chaib**

Press relation

[najettechaib@outlook.fr](mailto:najettechaib@outlook.fr)

+33 (0)6 18 38 11 14